Senior Director Global Regulatory Lead (Early Phase) - Oncology
Eli Lilly and Company- Full Time
- Senior (5 to 8 years)
Bristol-Myers Squibb
Candidates should possess a Bachelor’s degree and demonstrate at least 10 years of experience in portfolio strategy, preferably within the pharmaceutical or biotechnology industry, with a strong focus on medical cell therapy. They should have a proven track record of building and managing strategic relationships with external stakeholders, including academic institutions, industry leaders, and advocacy groups. Strong communication and presentation skills are essential, along with the ability to influence policy and regulatory decisions.
This Director will develop and deliver presentations, reports, and communication materials to external audiences, establishing and maintaining strong relationships with external partners such as academic institutions, professional societies, and patient advocacy groups. The role involves collaborating with internal and external stakeholders to influence policy, engaging with government agencies and advocacy groups, coordinating leadership engagements, and building regular insights reporting for senior management. Furthermore, the Director will collaborate with internal teams and congress management to ensure excellence in execution with congress strategies including internal and external communications and TLE management.
Develops and delivers biopharmaceutical medicines
Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.